|
|
???tair.name??? >
???browser.page.title.title???
|
Showing items 651201-651225 of 2303212 (92129 Page(s) Totally)
<< < 26044 26045 26046 26047 26048 26049 26050 26051 26052 26053 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2008-05 |
Phase I/II study of capecitabine and PHY906 in hepatocellular carcinoma
|
Yen, Y;So, S;Rose, M;Saif, MW;Chu, E;Chen, L;Liu, S;Foo, A;Tilton, R;Cheng, Y |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
|
Chia-Chi Lin; Taylor M; Boni V; Brunsvig P.F; Geater S.L; Salvagni S; Garrido Lopez P; ?zg?ro?lu M; Sriuranpong V; Ponce Aix S; Ascierto P.A; Fasolo A; Sezer A; Kowalski D.M; Faris J.E; Cameron S; Mataraza J; Wu H; Antona V; Ochoa de Olza M. |
| 國立臺灣大學 |
2008 |
Phase I/Ii Trail of Cultured Autologous Melanocytes and a New Transplantation Method for Vitiligo Treatment
|
洪楨邦; 詹融怡; 邱顯清; 林頌然; HONG, JIN-BON; CHAN, JUNG-YI; CHIU, HSIEN-CHING; LIN, SUNG-JAN |
| 國立臺灣大學 |
2008 |
Phase I/II trail of cultured autologous melanocytes and a new transplantation method for vitiligo treatment.
|
Hong, JB; She, BR; Chan, CC; Chiu, HC; Lin, SJ |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 國立成功大學 |
2020 |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai, J.;Deva, S.;Lee, J.S.;Lin, C.-C.;Yen, C.-J.;Chao, Y.;Keam, B.;Jameson, M.;Hou, M.-M.;Kang, Y.-K.;Markman, B.;Lu, C.-H.;Rau, K.-M.;Lee, K.-H.;Horvath, L.;Friedlander, M.;Hill, A.;Sandhu, Sandhu S.;Barlow, P.;Wu, C.-Y.;Zhang, Y.;Liang, Liang L.;Wu, J.;Paton, V.;Millward, Millward M. |
| 國立成功大學 |
2012-05 |
Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)
|
Cheng, AL (Cheng, Ann-Lii); Kang, YK (Kang, Yoon-Koo); Ryoo, BY (Ryoo, Baek-Yeol); Yen, CJ (Yen, Chia-Jui); Lim, HY (Lim, Ho Yeong); Oh, DY (Oh, Do-Youn); Austin, T (Austin, TaShara); Wang, Q (Wang, Qiang); Greenberg, J (Greenberg, Jonathan); Beckman, RA (Beckman, Robert A.); Kudo, M (Kudo, Masatoshi) |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Morikawa H.; Maki Y.; Tanaka T.; Ohtomo T.; Schwartz L.; Smith-Jones P.M.; Frenette C.; O’Neil B.; Shao Y.-Y.; Wan P.; Ma J.; Gansukh B.; Lyashchenko S.K.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Yen C.-J.; CHIH-HUNG HSU; Abou-Alfa G.K.; Abou-Alfa G.K.;Yen C.-J.;Chih-Hung Hsu;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Shao Y.-Y.;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Lin Z.-Z. |
| 臺大學術典藏 |
2021-08-11T03:46:39Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2021-08-31T06:29:38Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A. |
| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 國立成功大學 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, G.K.;Yen, C.-J.;Hsu, C.-H.;O’Donoghue, J.;Beylergil, V.;Ruan, S.;Pandit-Taskar, N.;Gansukh, B.;Lyashchenko, S.K.;Ma, J.;Wan, P.;Shao, Y.-Y.;Lin, Z.-Z.;Frenette, C.;O’Neil, B.;Schwartz, L.;Smith-Jones, P.M.;Ohtomo, T.;Tanaka, Tanaka T.;Morikawa, H.;Maki, Y.;Ohishi, N.;Chen, Y.-C.;Agajanov, T.;Boisserie, F.;Di, Laurenzio L.;Lee, R.;Larson, S.M.;Cheng, A.-L.;Carrasquilo, J.A. |
| 臺大學術典藏 |
2021-03-03T10:26:43Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HRþ advanced breast cancer
|
Tolaney, Sara M.; Im, Young Hyuck; Calvo, Emiliano; Yen-Shen Lu; Hamilton, Erika; Forero-Torres, Andres; Bachelot, Thomas; Maur, Michela; Fasolo, Angelica; Tiedt, Ralph; Nardi, Lisa; Stammberger, Uz; Abdelhady, Ahmed M.; Ruan, Shiling; Lee, Soo Chin |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
| 臺大學術典藏 |
2020-05-26T09:26:25Z |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Tan D.S.W.;Akimov M;Peng B;Zhao S;Pultar P;Glaser S;Chia V;Felip E;Su W.-C;Vansteenkiste J.F;Ahn M.-J;Chih-Hsin Yang;Lee D.H;Liu X;Kim D.-W;Zhang L;Wu Y.-L; Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. |
| 國立成功大學 |
2018 |
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
|
Wu, Y.-L.;Zhang, L.;Kim, D.-W.;Liu, X.;Lee, D.H.;Yang, J.C.-H.;Ahn, M.-J.;Vansteenkiste, J.F.;Su, W.-C.;Felip, E.;Chia, V.;Glaser, S.;Pultar, Pultar P.;Zhao, S.;Peng, B.;Akimov, M.;Tan, D.S.W. |
| 國立成功大學 |
2022 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
|
Santoro, A.;Su, W.-C.;Navarro, A.;Simonelli, M.;CH, Yang J.;Ardizzoni, Ardizzoni A.;Barlesi, F.;Hyoung, Kang J.;DiDominick, S.;Abdelhady, Abdelhady A.;Chen, X.;Stammberger, U.;Felip, E. |
| 國立交通大學 |
2014-12-08T15:04:52Z |
PHASE IDENTIFICATION AND ELECTRICAL-PROPERTIES IN ZNO-GLASS VARISTORS
|
LEE, YS; TSENG, TY |
| 臺大學術典藏 |
2002 |
Phase Identification And Growth Kinetics of the Intermetallic Compounds Formed during In-49Sn/Cu Soldering Reactions
|
ChuangTH; Wang, S. S.; Chang, S. Y.; Yu, C. L.; Chuang, T. H.; Yu, C. L.; Chang, S. Y.; Wang, S. S.; Chuang, T. H. |
| 國立臺灣大學 |
2002 |
Phase Identification And Growth Kinetics of the Intermetallic Compounds Formed during In-49Sn/Cu Soldering Reactions
|
Chuang, T. H.; Yu, C. L.; Chang, S. Y.; Wang, S. S. |
| 國立臺灣科技大學 |
1990 |
Phase Identification in Aged Au-Fe Alloys
|
C. C. Chou;H. Chen ;C. M. Wayman |
| 臺大學術典藏 |
2020-01-06T03:10:49Z |
Phase identification of the new 126 K Ba-Ca-Cu-O superconductor
|
Xue, Y.Y.; Sun, Y.Y.; Rusakova, I.; Ross, D.K.; Du, Z.L.; Wu, N.L.; Cao, Y.; Gao, L.; Hickey, B.; Chu, C.W.; NAE-LIH WU |
| 國家衛生研究院 |
2002-05 |
Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients
|
Liu, JM; Chen, LT; Chao, Y; Li, AFY; Wu, CW; Liu, TS; Shiah, HS; Chang, JY; Chen, CT; Wu, HW; Lin, WC; Lan, C; Whang-Peng, J |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
|
Price T.; Shen L.; Ma B.; Esser R.; Chen W.; Gibbs P.; Lim R.; ANN-LII CHENG |
Showing items 651201-651225 of 2303212 (92129 Page(s) Totally)
<< < 26044 26045 26046 26047 26048 26049 26050 26051 26052 26053 > >>
View [10|25|50] records per page
|
